Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $1.20 billion. The enterprise value is $978.67 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RCKT has 91.16 million shares outstanding. The number of shares has increased by 17.60% in one year.
| Current Share Class | 91.16M |
| Shares Outstanding | 91.16M |
| Shares Change (YoY) | +17.60% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 2.52% |
| Owned by Institutions (%) | 86.18% |
| Float | 71.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 10.75 |
| PB Ratio | 3.60 |
| P/TBV Ratio | 4.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.05, with a Debt / Equity ratio of 0.08.
| Current Ratio | 6.05 |
| Quick Ratio | 5.89 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -145.40 |
Financial Efficiency
Return on equity (ROE) is -59.27% and return on invested capital (ROIC) is -37.13%.
| Return on Equity (ROE) | -59.27% |
| Return on Assets (ROA) | -34.48% |
| Return on Capital (ROIC) | -37.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$962,981 |
| Employee Count | 268 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.21% in the last 52 weeks. The beta is 1.09, so RCKT's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | -41.21% |
| 50-Day Moving Average | 17.26 |
| 200-Day Moving Average | 21.89 |
| Relative Strength Index (RSI) | 23.59 |
| Average Volume (20 Days) | 853,256 |
Short Selling Information
The latest short interest is 11.90 million, so 13.05% of the outstanding shares have been sold short.
| Short Interest | 11.90M |
| Short Previous Month | 11.52M |
| Short % of Shares Out | 13.05% |
| Short % of Float | 16.74% |
| Short Ratio (days to cover) | 14.81 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -273.79M |
| Pretax Income | -253.26M |
| Net Income | -258.08M |
| EBITDA | -264.84M |
| EBIT | -273.79M |
| Earnings Per Share (EPS) | -$2.75 |
Full Income StatementBalance Sheet
The company has $235.66 million in cash and $25.64 million in debt, giving a net cash position of $210.02 million or $2.30 per share.
| Cash & Cash Equivalents | 235.66M |
| Total Debt | 25.64M |
| Net Cash | 210.02M |
| Net Cash Per Share | $2.30 |
| Equity (Book Value) | 329.77M |
| Book Value Per Share | 3.62 |
| Working Capital | 201.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$192.12 million and capital expenditures -$10.20 million, giving a free cash flow of -$202.32 million.
| Operating Cash Flow | -192.12M |
| Capital Expenditures | -10.20M |
| Free Cash Flow | -202.32M |
| FCF Per Share | -$2.22 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |